Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

Wanying Liu, Jiaying Wu, Xi Ming, Rubing Zheng, Sijia Yan, Chunrui Li, Xiaojian Zhu, Yi Xiao

Blood (2025) 146 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2025-7245

Published: 2025

Journal Articles

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies

Jiali Cheng, Li Zhu, Jia Wu, Yuhan Zeng, Xia Mao, Jue Wang, Liang Huang, Yi Xiao, Xiaoxi Zhou, Wei Mu, Xiaojian Zhu

Blood (2025) 146 (Supplement 1): 5949.

https://doi.org/10.1182/blood-2025-5949

Published: 2025

Journal Articles

Microbiota-derived 1,5-pentanediamine attenuates CD19 CAR-T function

Rubing Zheng, Xi Ming, delian Zhou, Jiaying Wu, Wanying Liu, Sijia Yan, Chunrui Li, Xiaojian Zhu, Yi Xiao

Blood (2025) 146 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2025-7619

Published: 2025

Journal Articles

Functional difference of CAR T-cells prepared from peripheral stem cell collections and peripheral lymphocyte collections

Xi Ming, Rubing Zheng, Jiaying Wu, Wanying Liu, delian Zhou, Sijia Yan, Chunrui Li, Xiaojian Zhu, Yi Xiao

Blood (2025) 146 (Supplement 1): 7705.

https://doi.org/10.1182/blood-2025-7705

Published: 2025

Journal Articles

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Xiwen Tong, Bin Xu, Shiyuan Zhang, Xiaojian Zhu, Mengyuan Li, Su Shuai, Yi Zhu, Zhenqian Huang, Yaya Wang, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Zhiping Huang, Yuanyan Tang, Hongbo Ren, Donghua Zhang

Blood (2024) 144 (Supplement 1): 4276.

https://doi.org/10.1182/blood-2024-205769

Published: 2024

Journal Articles

Reflecting In Vivo Spatio-Temporal Distribution Characteristics of CAR-T Cells through Real-World Clinical Samples

Man Zhang, Liting Chen, Caixia Chen, Jia Wei, Yicheng Zhang, Yi Xiao

Blood (2024) 144 (Supplement 1): 7125.

https://doi.org/10.1182/blood-2024-194628

Published: 2024

Journal Articles

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Shiyuan Zhang, Mengyuan Li, Xiaojian Zhu, Hao Zhou, Bin Xu, Xiwen Tong, Su Shuai, Yi Zhu, Yi Xiao, Liang Huang, Dengju Li, Wei Huang, Jia Wei, Mei Huang, Donghua Zhang

Blood (2024) 144 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2024-205864

Published: 2024

Journal Articles

Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study

Chunrui Li, Di Wang, Atsuhiko Hasegawa, Huining Liu, Ning An, Yuhan Bao, Meijuan Huang, Yi Xiao, Donghua Zhang, Miao Zheng, Wei Huang, Lijun Jiang

Blood (2023) 142 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2023-182556

Published: 2023

Journal Articles

Orelabrutinib Plus R-CHOP Regimen in Treatment-Naïve Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)

Yi Xiao, Jiaying Wu, Mi Zhou, Zhen Shang, Ming Zhu

Blood (2023) 142 (Supplement 1): 6289.

https://doi.org/10.1182/blood-2023-177563

Published: 2023

Journal Articles

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

JIA Wei, Min Xiao, Zekai Mao, Yang Cao, Yi Xiao, Fankai Meng, Yicheng Zhang, Jianfeng Zhou, Liang Huang

Blood (2021) 138 (Supplement 1): 94.

https://doi.org/10.1182/blood-2021-147278

Published: 2021

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138947

Published: 2020

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao, Jia Wei, Na Wang, Hao Xu, Min Xiao, Lifang Huang, Yang Cao, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Dengju Li, Yichen Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang

Blood (2020) 136 (4): 516–519.

https://doi.org/10.1182/blood.2020004907

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Blood (2020) 135 (1): 17–27.

https://doi.org/10.1182/blood.2019000017

Published: 2020

Includes: Supplemental data

Journal Articles

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Liang Huang, MDPhD, Na Wang, MD PhD, Yang Cao, Chunrui Li, MDPhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Xiaoxi Zhou, MD, PhD, Gaoxiang Wang, MDPhD, Zhenya Hong, MD, PhD, Miao Zhen, MD, PhD, Weixu Meng, MD PhD, Bin Zhang, PhD, Yicheng Zhang, MDPhD, Guido Marcucci, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1408.

https://doi.org/10.1182/blood-2018-99-113714

Published: 2018

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Yang Cao, Na Wang, MD PhD, Gaoxiang Wang, MD PhD, Yi Xiao, MD PhD, Liang Huang, MD PhD, Chunrui Li, MD PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, MD PhD, Jianfeng Zhou, MD PhD

Blood (2018) 132 (Supplement 1): 2054.

https://doi.org/10.1182/blood-2018-99-113827

Published: 2018

Journal Articles

Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30 + Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

Di Wang, MD PhD, Yi Xiao, MD PhD, Chunrui Li, MDPhD, Na Wang, MD PhD, Liang Huang, MDPhD, Yicheng Zhang, MDPhD, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2018-99-116741

Published: 2018

Journal Articles

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Liang Huang, MD PhD, Na Wang, MD PhD, Chunrui Li, MD PhD, Yang Cao, MD PhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Yicheng Zhang, MD PhD, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD

Blood (2017) 130 (Supplement 1): 846.

https://doi.org/10.1182/blood.V130.Suppl_1.846.846

Published: 2017

Journal Articles

Plasma Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Thrombocytopenia of Various Etiology

Yiqing Xu, MD PhD, Ying-Yi Xiao, PhD, Michael Simon, BA, Than Than Aye, MBBS, Komal Khiani, MD, Yang Liu, MD PhD, Yiwu Huang, MD PhD, Jack Burton, MD

Blood (2014) 124 (21): 4991.

https://doi.org/10.1182/blood.V124.21.4991.4991

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CAR T-cell therapy for refractory/relapsed primary breast lymphoma: A retrospective cohort study

First-in-human Phase I study of autologous CD5-knockout anti-CD5 CAR-T cells in CD5⁺ hematologic malignancies

Microbiota-derived 1,5-pentanediamine attenuates CD19 CAR-T function

Functional difference of CAR T-cells prepared from peripheral stem cell collections and peripheral lymphocyte collections

Efficacy of Decitabine in Combination with IA Versus IA in Patients with Newly Diagnosed AML, a Multicenter, Prospective, Randomized Controlled Trial

Reflecting In Vivo Spatio-Temporal Distribution Characteristics of CAR-T Cells through Real-World Clinical Samples

The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients

Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study

Orelabrutinib Plus R-CHOP Regimen in Treatment-Naïve Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells Following Autologous HSCT in Patients with B-NHL

Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30 + Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients

Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Plasma Vascular Endothelial Growth Factor (VEGF) Levels Correlate with Thrombocytopenia of Various Etiology

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only